Here is the design of a clinical trial:

Official Title: Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients

Included conditions:
- COVID-19

Study Armgroups:
- {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'Standard care only n = 10 patients.'}
- {'label': 'IVIG dose: 0.15 g/kg', 'type': 'EXPERIMENTAL', 'description': 'Standard Care + Single dose of 0.20 g/Kg anti-COVID-19 IVIG (experimental drug prepared at DUHS) n= 10 patients', 'interventionNames': ['Biological: SARS-CoV-2 antibody based IVIG therapy']}
- {'label': 'IVIG dose: 0.20 g/kg', 'type': 'EXPERIMENTAL', 'description': 'Standard Care + Single dose of 0.25 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients', 'interventionNames': ['Biological: SARS-CoV-2 antibody based IVIG therapy']}
- {'label': 'IVIG dose: 0.25 g/kg', 'type': 'EXPERIMENTAL', 'description': 'Standard Care + Single dose of 0.30 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients', 'interventionNames': ['Biological: SARS-CoV-2 antibody based IVIG therapy']}
- {'label': 'IVIG dose: 0.30 g/kg', 'type': 'EXPERIMENTAL', 'description': 'Standard Care + Single dose of 0.35 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients', 'interventionNames': ['Biological: SARS-CoV-2 antibody based IVIG therapy']}

Interventions:
- {'type': 'BIOLOGICAL', 'name': 'SARS-CoV-2 antibody based IVIG therapy', 'description': 'Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:\n\nAirway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics', 'armGroupLabels': ['IVIG dose: 0.15 g/kg', 'IVIG dose: 0.20 g/kg', 'IVIG dose: 0.25 g/kg', 'IVIG dose: 0.30 g/kg']}

Primary Outcomes:
- {'measure': '28 Days mortality', 'description': 'All cause mortality of participants will be monitored for 28 days to assess the safety and efficacy of IVIG treatment.', 'timeFrame': '28 days'}
- {'measure': 'Requirement of supplemental oxygen support', 'description': 'Number of days required for invasive or non-invasive oxygen supply during hospital stay as per oxygen saturation status of patient', 'timeFrame': '28 days'}
- {'measure': 'Number of days on assisted ventilation', 'description': 'Number of days a participant will be requiring assisted ventilation both invasive and noninvasive', 'timeFrame': '28 days'}
- {'measure': 'Days to step down', 'description': 'Shifting from ICU to ward', 'timeFrame': '28 days'}
- {'measure': 'Days to Hospital Discharge', 'description': 'Duration from day of enrollment in study to Day of hospital discharge', 'timeFrame': '28 days'}
- {'measure': 'Adverse events during hospital stay', 'description': 'Kidney failure, hypersensitivity with cutaneous or hemodynamic manifestations, aseptic meningitis, hemolytic anemia, leuko-neutropenia, transfusion related acute lung injury (TRALI)', 'timeFrame': '28 days'}
- {'measure': 'Change in C-Reactive Protein (CRP) levels', 'description': 'Change in C-Reactive Protein (CRP) levels from baseline will be used to monitor inflammation', 'timeFrame': '28 days'}
- {'measure': 'Change in neutrophil lymphocyte ratio', 'description': 'change in neutrophil lymphocyte ratio from baseline will be used to monitor inflammation', 'timeFrame': '28 days'}

Please estimate the sample size based on the assumption: 
Not explicitly stated in the provided paragraph.
Numbers to be randomised (sample size)
          Total 50 patients are randomised. The intervention arms consist of 40 participants divided in four groups of 10 participants while the comparator group consists of 10 patients.